Compare MAC & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAC | BIO |
|---|---|---|
| Founded | 1964 | 1952 |
| Country | United States | United States |
| Employees | 2845 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.0B |
| IPO Year | 1994 | 1994 |
| Metric | MAC | BIO |
|---|---|---|
| Price | $22.61 | $376.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | $20.50 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 2.5M | 250.5K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | 11.36 | ★ 142.61 |
| EPS | ★ N/A | N/A |
| Revenue | $1,013,983,000.00 | ★ $2,583,200,000.00 |
| Revenue This Year | N/A | $2.74 |
| Revenue Next Year | $4.80 | $3.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.43 | 0.65 |
| 52 Week Low | $16.03 | $236.73 |
| 52 Week High | $26.68 | $396.23 |
| Indicator | MAC | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 31.84 | 55.18 |
| Support Level | $22.13 | $284.88 |
| Resistance Level | $25.97 | $396.23 |
| Average True Range (ATR) | 0.54 | 9.71 |
| MACD | -0.04 | -2.69 |
| Stochastic Oscillator | 19.16 | 38.92 |
Macerich invests in premium mall assets. The company owns 27 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with a power center and six other real estate assets. The company's total portfolio has 39.2 million square feet of gross leasable area and averaged $899 sales per square foot over the 12 months ended in March 2026.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.